➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
Medtronic
Harvard Business School
Johnson and Johnson
McKinsey

Last Updated: August 4, 2020

DrugPatentWatch Database Preview

Details for Patent: 7,151,102

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,151,102 protect, and when does it expire?

Patent 7,151,102 protects LYNPARZA and is included in two NDAs.

This patent has thirty-five patent family members in twenty-four countries.

Summary for Patent: 7,151,102
Title:Phthalazinone derivatives
Abstract: A method of treatment of a disease of the human or animal body mediated by PARP comprising administering to such a subject a therapeutically effective amount of a compound of formula: ##STR00001## or an isomer, salt, solvate, chemically protected form, and prodrug thereof, wherein: A and B together represent an optionally substituted, fused aromatic ring; R.sub.C is represented by --L--R.sub.L, where L is of formula: --(CH.sub.2).sub.n1-Q.sub.n2-(CH.sub.2).sub.n3-- wherein n.sub.1, n.sub.2 and n.sub.3 are each selected from 0, 1, 2 and 3, the sum of n.sub.1, n.sub.2 and n.sub.3 is 1, 2 or 3 and Q is selected from O, S, NH, C(.dbd.O) or --CR.sub.1R.sub.2--, where R.sub.1 and R.sub.2 are independently selected from hydrogen, halogen or optionally substituted C.sub.1-7 alkyl, or may together with the carbon atom to which they are attached form a C.sub.3-7 cyclic alkyl group, which may be saturated (a C.sub.3-7 cycloalkyl group) or unsaturated (a C.sub.3-7 cycloalkenyl group), or one of R.sub.1 and R.sub.2 may be attached to an atom in R.sub.L to form an unsaturated C.sub.3-7 cycloalkenyl group which comprises the carbon atoms to which R.sub.1 and R.sub.2 are attached in Q, --(CH.sub.2).sub.n3-- (if present) and part of R.sub.L; and R.sub.L is optionally substituted C.sub.5-20 aryl; and R.sub.N is selected from hydrogen, optionally substituted C.sub.1-7 alkyl, C.sub.3-20 heterocyclyl, and C.sub.5-20 aryl, hydroxy, ether, nitro, amino, amido, thiol, thioether, sulfoxide and sulfone.
Inventor(s): Martin; Niall Morrison Barr (Cambridge, GB), Smith; Graeme Cameron Murray (Cambridge, GB), White; Charles Richard (Carlisle, GB), Newton; Roger Frank (Cornwall, GB), Douglas; Diane Gillian (Cornwall, GB), Eversley; Penny Jane (Cornwall, GB), Vile; Julia (Cornwall, GB)
Assignee: Kudos Pharmaceuticals Limited (Cambridge, GB) Maybridge PLC (Cornwall, GB)
Application Number:10/021,506
Patent Claim Types:
see list of patent claims
Compound; Composition;

Drugs Protected by US Patent 7,151,102

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Astrazeneca Pharms LYNPARZA olaparib CAPSULE;ORAL 206162-001 Dec 19, 2014 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Astrazeneca Pharms LYNPARZA olaparib TABLET;ORAL 208558-001 Aug 17, 2017 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
Astrazeneca Pharms LYNPARZA olaparib TABLET;ORAL 208558-002 Aug 17, 2017 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,151,102

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0026505.8Oct 30, 2000

International Family Members for US Patent 7,151,102

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 496034   Start Trial
Australia 2001295789   Start Trial
Australia 9578901   Start Trial
Brazil 0115062   Start Trial
Canada 2423279   Start Trial
China 100400518   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Baxter
Moodys
McKinsey
AstraZeneca
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.